Long-Term Results of Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: A Phase II Trial of the Radiation Therapy Oncology Group (RTOG 99-14)
Saved in:
| Title: | Long-Term Results of Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: A Phase II Trial of the Radiation Therapy Oncology Group (RTOG 99-14) |
|---|---|
| Authors: | Garden, Adam S.1, Harris, Jonathan2, Trotti, Andy3, Jones, Christopher U.4, Carrascosa, Luis5, Cheng, Jonathan D.5, Spencer, Sharon S.6, Forastiere, Arlene7, Weber, Randal S.8, Ang, K. Kian1 kianang@mdanderson.org |
| Source: | International Journal of Radiation Oncology, Biology, Physics. Aug2008, Vol. 71 Issue 5, p1351-1355. 5p. |
| Subjects: | Head & neck cancer, Cancer radiotherapy, Cancer treatment, Radiotherapy |
| Abstract: | Purpose: The feasibility of combining concomitant boost-accelerated radiation regimen (AFX-C) with cisplatin was previously demonstrated in this Phase II trial. This article reports the long-term toxicity, relapse patterns, and survival in patients with advanced head and neck carcinoma. Methods and Materials: Between April and November 2000, 84 patients with Stage III–IV HNC were enrolled, and 76 patients were analyzable. Radiation consisted of 72 Gy over 6 weeks. Cisplatin dose was 100 mg/m2 on Days 1 and 22. Tumor and clinical status were assessed, and acute-late toxicities were graded. Results: The median follow-up for surviving patients is 4.3 years. The 2- and 4-year locoregional failure rates were 33% and 36%, respectively, and the 2- and 4-year survival rates were 70% and 54%, respectively. The worst overall late Grade 3 or 4 toxicity rate was 42%. The prevalence rates of a gastrostomy at any time during follow-up, at 12 months, and at 48 months were 83%, 41%, and 17%, respectively. Five of 36 patients (14%) alive and without disease at last follow-up were gastrostomy-tube dependent. Conclusion: These data of long-term follow-up of patients treated with AFX-C with cisplatin show encouraging results with regard to locoregional disease control and survival, with few recurrences after 2 years. The late toxicity rates are relatively high. However, although prolonged dysphagia was noted in our preliminary report, its prevalence does decreased over time. A Phase III trial comparing AFX-C plus cisplatin against standard radiation plus cisplatin has completed accrual. [Copyright &y& Elsevier] |
| Copyright of International Journal of Radiation Oncology, Biology, Physics is the property of Pergamon Press - An Imprint of Elsevier Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: egs DbLabel: Engineering Source An: 33343152 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Long-Term Results of Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: A Phase II Trial of the Radiation Therapy Oncology Group (RTOG 99-14) – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Garden%2C+Adam+S%2E%22">Garden, Adam S.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Harris%2C+Jonathan%22">Harris, Jonathan</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Trotti%2C+Andy%22">Trotti, Andy</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Jones%2C+Christopher+U%2E%22">Jones, Christopher U.</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Carrascosa%2C+Luis%22">Carrascosa, Luis</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Cheng%2C+Jonathan+D%2E%22">Cheng, Jonathan D.</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Spencer%2C+Sharon+S%2E%22">Spencer, Sharon S.</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Forastiere%2C+Arlene%22">Forastiere, Arlene</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Weber%2C+Randal+S%2E%22">Weber, Randal S.</searchLink><relatesTo>8</relatesTo><br /><searchLink fieldCode="AR" term="%22Ang%2C+K%2E+Kian%22">Ang, K. Kian</searchLink><relatesTo>1</relatesTo><i> kianang@mdanderson.org</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22International+Journal+of+Radiation+Oncology%2C+Biology%2C+Physics%22">International Journal of Radiation Oncology, Biology, Physics</searchLink>. Aug2008, Vol. 71 Issue 5, p1351-1355. 5p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Head+%26+neck+cancer%22">Head & neck cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+radiotherapy%22">Cancer radiotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+treatment%22">Cancer treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Radiotherapy%22">Radiotherapy</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Purpose: The feasibility of combining concomitant boost-accelerated radiation regimen (AFX-C) with cisplatin was previously demonstrated in this Phase II trial. This article reports the long-term toxicity, relapse patterns, and survival in patients with advanced head and neck carcinoma. Methods and Materials: Between April and November 2000, 84 patients with Stage III–IV HNC were enrolled, and 76 patients were analyzable. Radiation consisted of 72 Gy over 6 weeks. Cisplatin dose was 100 mg/m2 on Days 1 and 22. Tumor and clinical status were assessed, and acute-late toxicities were graded. Results: The median follow-up for surviving patients is 4.3 years. The 2- and 4-year locoregional failure rates were 33% and 36%, respectively, and the 2- and 4-year survival rates were 70% and 54%, respectively. The worst overall late Grade 3 or 4 toxicity rate was 42%. The prevalence rates of a gastrostomy at any time during follow-up, at 12 months, and at 48 months were 83%, 41%, and 17%, respectively. Five of 36 patients (14%) alive and without disease at last follow-up were gastrostomy-tube dependent. Conclusion: These data of long-term follow-up of patients treated with AFX-C with cisplatin show encouraging results with regard to locoregional disease control and survival, with few recurrences after 2 years. The late toxicity rates are relatively high. However, although prolonged dysphagia was noted in our preliminary report, its prevalence does decreased over time. A Phase III trial comparing AFX-C plus cisplatin against standard radiation plus cisplatin has completed accrual. [Copyright &y& Elsevier] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of International Journal of Radiation Oncology, Biology, Physics is the property of Pergamon Press - An Imprint of Elsevier Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=33343152 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.ijrobp.2008.04.006 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 5 StartPage: 1351 Subjects: – SubjectFull: Head & neck cancer Type: general – SubjectFull: Cancer radiotherapy Type: general – SubjectFull: Cancer treatment Type: general – SubjectFull: Radiotherapy Type: general Titles: – TitleFull: Long-Term Results of Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: A Phase II Trial of the Radiation Therapy Oncology Group (RTOG 99-14) Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Garden, Adam S. – PersonEntity: Name: NameFull: Harris, Jonathan – PersonEntity: Name: NameFull: Trotti, Andy – PersonEntity: Name: NameFull: Jones, Christopher U. – PersonEntity: Name: NameFull: Carrascosa, Luis – PersonEntity: Name: NameFull: Cheng, Jonathan D. – PersonEntity: Name: NameFull: Spencer, Sharon S. – PersonEntity: Name: NameFull: Forastiere, Arlene – PersonEntity: Name: NameFull: Weber, Randal S. – PersonEntity: Name: NameFull: Ang, K. Kian IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 08 Text: Aug2008 Type: published Y: 2008 Identifiers: – Type: issn-print Value: 03603016 Numbering: – Type: volume Value: 71 – Type: issue Value: 5 Titles: – TitleFull: International Journal of Radiation Oncology, Biology, Physics Type: main |
| ResultId | 1 |
